Welcome to Genafor − Open Services for Medical Research

Donnerstag, 10. April 2008

Slides are available online as image files. Please write to info@genafor.org if we should send you a PDF file.

Zeit Vorträge

09:30 - 12:00

Chair: Ulrich Spengler, Michael Roggendorf
HBV Resistenzbestimmung, Genotypisierung, Internet Tools up-date Klinische Anwendung / Primärresistenz bei HBV HBV Escape Mutants in occult and reactivated infectiosn, Medeora hepatitis, Falldiskussion, Phänotypische Resistenz

 

Phenotypic assays for HBV resistance tests
Maria Fraune

 

HBV Testing for drug resistance and resistance interpretation
Martin Däumer, Institute of Immunology and Genetics Kaiserslautern

 

HIV-GRADE HBV-Tool
Martin Obermeier, Medizinisches Labor Berg

 

Hepatitis B -Resistencemanagementin the clinical setting
A. Erhardt, Klinik für Gastroenterologie, Hepatologieund InfektiologieUniversitätsklinikum Düsseldorf

 

Escape mutations in occult and reactivated hepatitisB virusinfection
Wolfram H. Gerlich, Institute for Medical Virology

 

MEDEORA-Hepatitis

 

HBV Aktuelle Therapieleitlinien, Resistenzproblematik und Erfahrungen aus der Praxis
Andreas Erhardt, Universitätsklinikum Düsseldorf

 

HIV-Coinfections, HIV-HBV/HCV infections in RESINA-patients
Martin Vincentz, Inst. of Virology, Uni Köln

 

Impact of the Variability of the Hepatitis-B-Virus surface Antigen (sAg) on Detection in different Analytic Systems
Maria Fraune

12:00 - 12:20

Laudatio Lutz Gürtler
Josef Eberle, Pettenkofer-Institut München

12:20 - 13:30

Chair: Eva Wolf, Lutz Gürtler
HIV ARCA, Internet tools up-date, Resistenzbestimmung, Genotypisierung, Klinische Anwendung / Relevanz

 

The ARCA database, Features and perspectives
Maurizio Zazzi, University of Siene, Italy

 

New Drugs/Targets - New Challenges
Martin Stürmer, Institute for Medical Virology, University Clinic Frankfurt/Main

 

Guiding Treatment Selection: past, present, and futureArevirMeeting
André Altmann,Computational Biology and applied Algorithmics, MPII Saarbrücken

 

Clinical application / relevance
H.-J. Stellbrink, ICH Hamburg

14:30 - 14:45

Chair: Rolf Kaiser
MOdifies RNA Technology (MRT)

 

Modified RNA (MRT)
Heike Körber

14:45 - 16:45

Chair: Herbert Pfister, Dieter Häussinger
Kohorten Arevir, EuResist, Kompetenznetz HIV/Aids, RegaDB

 

Analysis of resistance mutations of HI-Virus
Eugen Schülter, Virologie Köln

 

EuResist
Mattia Prosperi, University of "Roma TRE"

 

Establishing a resistance database within the Competence Network for HIV/AIDS
Klaus Jansen, BMBF

 

Rega Institute for Medical Research
Kristof Theys, Katholieke Universiteit Leuven

 

RegaDB
Pieter Libin, Katholieke Universiteit Leuven

17:00 - 19:00

Chair: Bernd Kupfer, Martin Däumer
HIV Integrase, GAG mutation, VIRCO TYPE

 

Integrase Inhibitoren
Stefan Esser, Uni Hautklinik Essen

 

Analysis of IntegraseInhibitor (INI) resistance in ART-and INI-naïve and -experienced patients
Nadine Sichtig, Virologie Köln

 

geno2pheno [integrase]
André Altmann,Computational Biology and applied Algorithmics, MPII Saarbrücken

 

HIV Gag under multiple pressure - protease inhibitors, immune system and replication capacity
Elena Knops, Virologie Köln

 

Updated virtual Phenotype-LM approach and Clinical Cut-Offs for the virco® TYPE HIV-1 Resistance Analysis
M. Van Houtte L, BVBA

 

Freitag, 11. April 2008

Zeit Vorträge

09:00 - 09:30

Selbsthilfegruppe HIV/ HCV

 

PrisMed eine wisssenschaftsorientierte Selbsthilfegruppe für HIV/HCV, Resistenzen und AD(H)S
Sedlmayer

09:30 - 13:30

Chair: Gerd Fätkenheuer, Eva Wolf
HIV: Genotypisiserung / Resistenzbestimmung Klinische Anwendung / Relevanz Coreceptor, Ultra deep sequencing

 

CCR5 Antagonists In Clinical Practice
Björn Jensen, InfektiologieInfektiologieUniversitUniversitäätsklinikum Dtsklinikum Düüsseldorf

 

X-TrackC: a "genosorting"method for highly sensitive determination of HIV co-receptor tropism
François Hamy, InPheno

 

HIV HIV-1 tropism prediction
Mattia Prosperi, University of "Roma TRE"

 

V3 Loop Sequence Space Analysis
Kasia Bozek, MPII Saarbrücken

 

Evolution of HIV geno-and phenotypes during anti-retroviral therapy
Barbara Schnierle, Paul-Ehrlicher Institut

 

Genotypic analysis of coreceptor usage. New developments and applications for geno2pheno [coreceptor]
Alexander Thielen, MPII Saarbrücken

 

Genotypic Tropism testing in Germany, Comparison of TROFILE® and seven genotypic interpretation approaches
Martin Obermeier, Medizinisches Labor Berg

 

Multicentre study to evaluate the relation study between the efficacy of treatment with the CCR5 inhibitor Maraviroc and HIV-1 co-receptor tropism as determined by V3 loop sequencing
Vandekerckhove Linos, Hospital Ghent, Belgium

 

Minorities: "ultra deep sequencing"of HIV V3
Martin Däumer, Institute of Immunology and Genetics, Kaiserslautern

 

Coreceptor Prediction Consensus
Hauke Walter, Martin Obermeier, Alexander Thielen, Martin Däumer, Patrick Braun, Klaus Korn, Thomas Berg, Eva Wolf, Harm Müller, Josef Eberle, Rolf Kaiser

14:30 - 17:00

Chair: Hans-Wilhem Doerr, Thomas Harrer
Verbundprojekte Arevir / RESINA. Minoritäten - klinische relevanz RKI Serokonverter, DAGNAE- verbundprojekt Qualitätsmanagement

 

New graphical user interface for geno2pheno resistance
Joachim Büch, MPII Saarbrücken

 

Arevir Update: MPI Informatics
Thomas Lengauer, MPII Saarbrücken

 

HAART in Patients with Primary HIV Drug Resistance: The RESINA Study
Mark Oette, Uniklinik Düsseldorf

 

Influence of the K103N minor variants in therapy-naïve HIV-1 infected patients on clinicaloutcome
Melanie Balduin, Virology Cologne

17:00 - 17:45

Chair: Mark Oette
PEI Corus, Euresist, HIV-Grade, Models for HIV frug resistance interpretation

 

Transmission of resistant HIV in patients with a known date of infection
Barbara Bartmeyer, Robert Koch-Institute, Berlin

 

Co-receptorusageas a marker for specific HIV diagnostics with high sensitivity
Stefan Reuter und Daniel Hoffmann, Uni Düsseldorf, Uni Essen

 

Co-Receptor usage as marker for specific HIV diagnostics with high sensitivity
Daniel Hoffmann, Uni Essen

 

EuResist: An integrated system for management of antiretroviral drug resistance
Francesca Incardona, Informa s.r.l.

17:45 - 18:30

Chair: Stefan Esser, Heribert Knechten
HIV and HLA Eiführung in die HLA Typisierung, Coerrelations between HIV drug resistance mutation and HLA of therapy-expirienced and terapy-naïve patients

 

HLA and Drug Resistance
Thomas Harrer, Dept. of Medicine 3, University Hospital Erlangen

 

Correlations between transmitted HIV-1 drug resistance mutations and the HLA of therapy-naive HIV-patients
Finja Schweitzer

Download Programm (PDF)